ACRS Aclaris Therapeutics Inc.

25.29
-0.06  -0%
Previous Close 25.35
Open 25.55
Price To book 4.02
Market Cap 676166515
Shares 26,736,517
Volume 356,104
Short Ratio 9.74
Av. Daily Volume 283,037

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017.
ATI-50002
Patchy alopecia areata
Phase 2 trial to be initiated 2H 2017.
ATI-50001
Alopecia totalis and alopecia universalis
PDUFA date is December 24, 2017
A-101
Seborrheic keratosis (SK)
Phase 2 data released August 2016. Phase 2b trial initiation announced June 29, 2017.
A-101
Common warts (verruca vulgaris)

Latest News

  1. Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
  2. Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  3. Aclaris Therapeutics Announces Issuance of Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders
  4. Aclaris Therapeutics to Attend Upcoming Investor Conferences
  5. Edited Transcript of ACRS earnings conference call or presentation 8-Aug-17 12:30pm GMT
  6. Aclaris Announces Pricing of Public Offering of Common Stock
  7. Aclaris Announces Proposed Public Offering of Common Stock
  8. Aclaris Announces Appointment of Andrew Schiff to Board of Directors
  9. Aclaris reports 2Q loss
  10. [$$] Aclaris Therapeutics Buys Confluence Life Sciences in $100 Million Deal
  11. Aclaris Therapeutics Reports Second Quarter 2017 Financial Results
  12. Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.
  13. Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call
  14. Aclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis
  15. Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata
  16. UPDATE - Aclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
  17. Aclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
  18. Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts